Drug Profile
Sotatercept - Merck & Co
Alternative Names: ACE-011; ACTRIIA-Fc - Merck & Co; MK-7962; Sotatercept-csrk - Merck & Co; WINREVAIRLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Developer Acceleron Pharma; Celgene Corporation; Indiana University; Merck & Co; University of Texas M. D. Anderson Cancer Center
- Class Antianaemics; Antihypertensives; Antineoplastics; Immunoglobulin Fc fragments; Osteoporosis therapies; Recombinant fusion proteins
- Mechanism of Action Activin inhibitors; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Pulmonary arterial hypertension
- Phase II Pulmonary hypertension
- Discontinued Anaemia; Beta-thalassaemia; Bone metastases; Chemotherapy-induced anaemia; Diamond-Blackfan syndrome; Myelodysplastic syndromes; Myelofibrosis; Postmenopausal osteoporosis; Renal osteodystrophy; Sickle cell anaemia; Vascular calcification
Most Recent Events
- 26 Mar 2024 Merck & Co intends to launch sotatercept for Pulmonary arterial hypertension in the US (SC) in April 2024
- 26 Mar 2024 Efficacy data from a phase III STELLAR trial in Pulmonary artificial hypertension released by Merck
- 20 Nov 2023 Efficacy and adverse events data from a phase III SOTERIA trial for Pulmonary arterial hypertension presented at the 33rd Annual Congress of the European Respiratory Society (ACEPS-2023)